Key Points
- Director Joseph Capper bought 25,000 TELA Bio shares at an average price of $1.02, investing $25,500 and increasing his holdings by 83.82% to 54,827 shares.
- TELA Bio reported a quarterly loss of $0.20 per share, missing estimates by $0.03, while revenue of $19.29 million also fell short of expectations. Analysts expect a full-year loss of $0.76 per share.
- The stock carries a consensus “Hold” rating and a $2.20 price target, while institutional investors own 94.35% of the company.
TELA Bio, Inc. (NASDAQ:TELA - Get Free Report) Director Joseph Capper bought 25,000 shares of the stock in a transaction on Monday, September 14th. The stock was acquired at an average price of $1.02 per share, with a total value of $25,500.00. Following the completion of the acquisition, the director owned 54,827 shares of the company's stock, valued at $55,923.54. This represents a 83.82% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
TELA Bio Price Performance
Shares of TELA opened at $1.18 on Thursday. The firm has a market cap of $53.27 million, a PE ratio of -1.53 and a beta of 1.36. TELA Bio, Inc. has a 52-week low of $0.50 and a 52-week high of $1.69. The business's 50 day moving average price is $0.78 and its two-hundred day moving average price is $0.79. The company has a debt-to-equity ratio of 8.82, a quick ratio of 2.38 and a current ratio of 2.99.
TELA Bio (NASDAQ:TELA - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.03). TELA Bio had a negative net margin of 51.53% and a negative return on equity of 1,320.81%. The company had revenue of $19.29 million for the quarter, compared to analyst estimates of $20.01 million. On average, equities analysts anticipate that TELA Bio, Inc. will post -0.76 EPS for the current year.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of TELA Bio in a research note on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, TELA Bio currently has a consensus rating of "Hold" and a consensus price target of $2.20.
Read Our Latest Stock Analysis on TELA Bio
Institutional Trading of TELA Bio
Several hedge funds have recently bought and sold shares of TELA. Nantahala Capital Management LLC purchased a new stake in TELA Bio in the 2nd quarter worth about $4,420,586. Stonepine Capital Management LLC purchased a new stake in TELA Bio during the second quarter valued at about $1,996,820. BlackRock Inc. purchased a new stake in TELA Bio during the second quarter valued at about $281,000. UP Strategic Wealth Investment Advisors LLC bought a new position in TELA Bio during the second quarter worth about $91,000. Finally, WealthTrust Axiom LLC boosted its position in TELA Bio by 39.1% during the fourth quarter. WealthTrust Axiom LLC now owns 322,588 shares of the company's stock worth $381,000 after purchasing an additional 90,650 shares during the period. Institutional investors and hedge funds own 94.35% of the company's stock.
About TELA Bio
(
Get Free Report)
TELA Bio, Inc is a medical technology company focused on developing and commercializing implantable products for soft-tissue reconstruction. Its products are designed to support the repair and reinforcement of damaged or weakened soft tissue, including tissue affected by hernias, abdominal wall defects and other reconstructive procedures.
The company's principal product platform is OviTex Reinforced Tissue Matrix, a family of biologic implants that combines extracellular matrix tissue with a polymer reinforcement structure.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
